 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...7071727374757677787980...8687» |
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Pricing: $1800.00 for a Prolia shot from the doc and $1200.00 from the Walmart. Cost must be $600.00 or so. (Twitter) - Jul 6, 2019
- | Review, Journal: Current and Emerging Therapeutic Options for the Management of Rare Skeletal Diseases. (Pubmed Central) - Jul 6, 2019
Additionally, new therapeutic options could be achieved through increased awareness, not only in the field of pediatrics but also in prenatal and obstetric specialties. Presenting new therapeutic options might influence families in their decision of whether or not to terminate a pregnancy with a child with a skeletal disease.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Journal, Checkpoint inhibition: Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. (Pubmed Central) - Jul 6, 2019
The combination therapy of metastatic melanoma with PD-1i and denosumab was feasible without unexpected safety issues and showed a promising efficacy signal. Further investigation in prospective studies is needed.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
#Teriparatide or #Denosumab: Which to use for #osteoporosis after #bisphosphonates? #fractureprevention #JCEM #Prolia #Forteo @EndoSocJournals @kaz_yos @DanielHSolomon https://t.co/qgaCXYv6A2 (Twitter) - Jul 6, 2019
- || Thalidomide Lenalidomide Pomalidomide Bortezomib Carfilzomib Ixazomib Denosumab Panobinostat Selinexor Daratumumab Elotuzumab More to come! All approved in the last two decades. What an era. (Twitter) - Jul 4, 2019
- | Xofigo (radium Ra-223 dichloride) / Bayer
Journal: Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223? (Pubmed Central) - Jul 4, 2019
Bone scintigraphy flare in patients undergoing therapy with radium-223 was observed. Bone scintigraphy data acquired during treatment with radium-223 should be interpreted with caution, and treatment should not be changed according to increase in number of lesions on bone scintigraphy alone after 3 cycles of radium-223.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Healthier bones and less recurrence with denosumab. (Pubmed Central) - Jul 4, 2019
Bone scintigraphy data acquired during treatment with radium-223 should be interpreted with caution, and treatment should not be changed according to increase in number of lesions on bone scintigraphy alone after 3 cycles of radium-223. No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients. (Pubmed Central) - Jul 3, 2019
Denosumab was associated with increased risk of renal function decline in male patients (AHR, 1.78; p = 0.0132), patients with renal insufficiency (AHR, 1.5; p = 0.0132), and patients with acute kidney injury during the study period (AHR, 1.53; p = 0.0154). Conclusively, denosumab may exert cardiovascular benefits in patients with good adherence but may have renal disadvantages in certain conditions and thus must be used with caution.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
#VoglNY : "Denosumab Prevents Neither Breast Cancer Relapse Nor Death" (Twitter) - Jul 2, 2019
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
May be zometa vs xgeva (Twitter) - Jul 2, 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Denosumab generics already making it within easy reach for people now. Really useful in terms of hypercalcaemia as well. (Twitter) - Jul 1, 2019
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Retrospective data, Head-to-Head: With denosumab vs. zoledronate, some KOLs claim denosumab yields superior PFS — based on a post-hoc analysis in a noninferiority study. A drug with no single-agent activity yielding a huge PFS improvement based on a bad analysis should really give them pause. But it doesn’t. (Twitter) - Jun 29, 2019
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
It’s not a weak defense. Do the math. See time to skeletal event numbers in months. Explain how median PFS with denosumab is almost twice as long than time to a skeletal event considered important enough to be primary endpoint. Also look at the curves. (Twitter) - Jun 29, 2019
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical: Either primary analysis of equivalence for bone endpoints (to get approval) was based on meaningless bone events or the PFS calculation is wrong In any case if one thinks denosumab produces PFS gain that is >50% more than Dara (& similar to CAR-T)- they can go ahead & believe it (Twitter) - Jun 29, 2019
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, FDA event: Either the primary analysis of equivalence for bone endpoints (to get FDA approval) was based on meaningless bone events or the PFS calculation is wrong. In any case if you think denosumab produces PFS that is 50-70% more than Dara and similar to CAR-T - go ahead and believe it (Twitter) - Jun 29, 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions? (Pubmed Central) - Jun 28, 2019
Conclusively, denosumab may exert cardiovascular benefits in patients with good adherence but may have renal disadvantages in certain conditions and thus must be used with caution. No abstract available
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Already we know in myeloma that a drug that is 20 times more expensive ($2000 vs $70) is being used even though data show its only equivalent to cheaper drug, and worse— cannot be stopped easily. Nice. (Denosumab vs Zometa). I cannot be confident that this is not driven by $. (Twitter) - Jun 28, 2019
- | Prolia (denosumab) / Amgen
Trial primary completion date: AOST1321: Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Jun 28, 2019
P2, N=90, Active, not recruiting, Sponsor: Children's Oncology Group
No abstract available Trial primary completion date: Aug 2019 --> Dec 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. (Pubmed Central) - Jun 28, 2019
In summary, introduction of ZA and denosumab has protected patients with bone metastasis from serious bone complications and improved their quality of life. Ongoing research will hopefully guide the optimal use of these agents to help maintain bone health in patients with solid tumours.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
1. It remains unclear whether Denosumab can ever be safely discontinued or de-escalated after achieving a deep hematologic response, since it has a reversible mechanism of action. (Twitter) - Jun 27, 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Yes! In recent example we expedited diagnosis, lowered ca with IVF, and then started CyBorD given extensive light chain burden. But point echoing yours re: hesitancy around denosumab for theoretical hypocalcemia and rebound bone disease. (Twitter) - Jun 26, 2019
- | Zinbryta (daclizumab) / Biogen, AbbVie, Tivicay (dolutegravir) / GSK, ViiV Healthcare
Journal, Adverse events: Pharmacovigilance update (Pubmed Central) - Jun 26, 2019
Cobicistat-boosted antiretrovirals exposure is decreased during pregnancy. Fourth generation pills containing drospirenone : a greater propensity to prolong the QT interval than 2nd generation pills.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. (Pubmed Central) - Jun 23, 2019
A multivariable logistic analysis showed that the prednisolone dose at baseline was associated with the clinical response to denosumab. In a real-world setting, denosumab was effective and safe for treating GIOP patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drug treatment.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Bone and calcium metabolism associated with malignancy. Bone and calcium metabolism associated with malignancy. (Pubmed Central) - Jun 23, 2019
Zoledronic-acid and denosumab are currently available and denosmab seems to be superior to zoledronic-acid in inhibiting osteoclastic activity. Although both of these are safe drugs, several rare but serious adverse events need to be cautious like osteonecrosis of the jaw, hypocalcemia, renal dysfunction and atypical fracture.
- | Clinical, Journal: Bone and calcium metabolism associated with malignancy. Bone metastasis of prostate cancer:overview of clinical features and treatments. (Pubmed Central) - Jun 23, 2019
New androgen targeted agents, enzalutamide and abiraterone, or taxans, docetaxel and cabazitaxel, show clinical efficacy for bone metastasis of prostate cancer...For this category, enzalutamide and apalutamide have been approved for patients with nonmetastatic castration-resistant prostate cancer. Treatment and follow-up strategy is now dramatically changed in the area of bone metastasis of prostate cancer.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia. (Pubmed Central) - Jun 23, 2019
MAH can be divided into two categories:humoral hypercalcemia of malignancy(HHM)caused by a systemic soluble factor secreted by the tumor;and local osteolytic hypercalcemia(LOH)in which tumor cells in situ enhance bone resorption. The standard treatment of MAH is intense hydration along with antiresorptive medications such as calcitonin, bisphosphonate and denosumab.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer. (Pubmed Central) - Jun 23, 2019
And recently, our study revealed even in Japanese breast cancer patients denosumab injection every 6 months showed significant increase in bone density. The number of women suffering from breast cancer in Japan reaches approximately 90,000 per year, a considerable number is estimated as a preliminary group of CTIBL, so early appropriate measures are desired.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Zytiga (abiraterone acetate) / J&J
Journal: Bone and calcium metabolism associated with malignancy. Bone management of prostate cancer in the novel anti-androgen era. (Pubmed Central) - Jun 23, 2019
Because abiraterone with glucocorticoid therapy induces stronger bone resorption, it is recommended to start denosumab simultaneously. Ra-223, bone seeking radiopharmaceuticals should not be used with abiraterone and predonisone because of high incidence of fracture and death.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
I was the perfect candidate for PROLIA-DenosuMAB I tripped over my dog+broke my hip+shoulder--See Crohn's I had taken enough drugs I said no--see my current Golf challenges. See my L5-S1 Discectomy+my Nightmare afterwards--CNS Fluid Leak. Why? See Fungal Dis-from 10yr AB 4 Acne (Twitter) - Jun 23, 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Anti-bone resorbing treatment for rheumatoid arthritis. (Pubmed Central) - Jun 22, 2019
In the DRIVE study denosumab inhibited the progression of bone erosion in Japanese patients with RA. Thus, differential efficacy of different therapies in bone destruction and osteoporosis would warrant further study to clarify the mechanisms of bone and joints diseases.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Review, Journal: Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child: case report and literature review. (Pubmed Central) - Jun 22, 2019
Surgical treatment is aimed at removing the tumor and relieving the symptomatic spinal cord compression. Use of denosumab as neoadjuvant therapy for juvenile xanthogranuloma involving the spine has not been reported previously.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Review, Journal: Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. (Pubmed Central) - Jun 22, 2019
...AFFs are primarily associated with prolonged bisphosphonate (BP) exposure, but have also been reported in unexposed patients and those receiving denosumab for osteoporosis and metastatic bone disease...Teriparatide may advance AFF healing but few data support its efficacy. Greater understanding of biological and genetic predisposition to AFF may allow characterization of individual risk prior to initiating osteoporosis therapy and help allay fear in those at low risk for this complication, which remains rare in comparison to the osteoporotic fractures prevented by antiresorptive therapy.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Immobilization of Denosumab on Titanium Affects Osteoclastogenesis of Human Peripheral Blood Monocytes. (Pubmed Central) - Jun 22, 2019
PBMCs on cDMAB-titanium also changed SEM cell morphology. In conclusion, the results indicate that cDMAB reduces osteoclast formation and has the potential to reduce osteoclastogenesis on titanium surfaces.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities. (Pubmed Central) - Jun 21, 2019
...Using medication administration data, we identified antiresorptive (bisphosphonates and denosumab) and vitamin D supplement use among residents with osteoporosis...Vitamin D was consistently used by more than 60% of residents and was higher among those with fracture history. Greater attention to the treatment of osteoporosis treatment rates among this high fracture-risk population is warranted.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Management of nonmetastatic castration-resistant prostate cancer. (Pubmed Central) - Jun 20, 2019
Greater attention to the treatment of osteoporosis treatment rates among this high fracture-risk population is warranted. The importance of reducing mortality and morbidity associated with metastasis has led to the acceptance of new primary endpoints in the design of trials for nmCRPC and might result in widespread approval of new agents for this disease state.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Metastatic calcinosis cutis due to refractory hypercalcaemia responsive to denosumab in a patient with multiple sclerosis. (Pubmed Central) - Jun 19, 2019
Normocalcaemia was restored with the off-label use of denosumab, usually reserved for hypercalcaemia of malignancy and intractable osteoporosis. We discuss potential aetiologies of this patient's hypercalcaemia, calcinosis cutis diagnosis and management and the off-label use of denosumab.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
What about drug holidays in osteoporosis? Ok with bisphosphonates but NOT with denosumab. #BSG2019 (Twitter) - Jun 17, 2019
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
In Brazil Denosumab is almost the same price of zoledrinic acid, so why don’t use monoclonal? I know the prices is very different from country to country. (Twitter) - Jun 17, 2019
- | abaloparatide (BA058) / Radius, Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
Review, Journal: Bone: best papers of the year 2017. (Pubmed Central) - Jun 15, 2019
We discuss potential aetiologies of this patient's hypercalcaemia, calcinosis cutis diagnosis and management and the off-label use of denosumab. These papers offer a hopeful outlook for a better treatment and management of patients with osteoporosis and other metabolic bone diseases anno 2018.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Xofigo (radium Ra-223 dichloride) / Bayer
Biomarker, Journal, IO Biomarker: Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. (Pubmed Central) - Jun 15, 2019
Ongoing studies will explore the impact of combining bone-targeted therapy with investigational therapeutic agents such as immunotherapy, for advanced prostate cancer. Future studies should strive to develop biomarkers of response, in order to improve efficacy and cost-effectiveness of these agents.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evomate (raloxifene hydrochloride) / Shreya Life Sciences
Clinical, Journal, Real-World Evidence: Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. (Pubmed Central) - Jun 15, 2019
Future studies should strive to develop biomarkers of response, in order to improve efficacy and cost-effectiveness of these agents. In summary, reductions in fracture incidence over time were observed in cohorts of patients treated with osteoporosis therapies.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal, Real-World Evidence: Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis. (Pubmed Central) - Jun 15, 2019
Approximately one-third of patients had no subsequent treatment immediately after teriparatide. Monitoring persistence and considering subsequent drugs for osteoporosis are necessary for teriparatide treatment.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Cancer Treatment-Induced Bone Loss(CTIBL) (Pubmed Central) - Jun 15, 2019
...It has been reported that bisphosphonates and denosumab prevent the bone loss and fractures in a part of these patients...However, there are some discrepancies in the evaluation and treatment of the patients in these guidelines. It is necessary to establish a management plan for patients with CTIBL in Japan in the future.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: c-ANCA vasculitis after initiation of denosumab. (Pubmed Central) - Jun 15, 2019
Once suspicion for drug-induced vasculitis arises, the offending agent should be discontinued and immunosuppressive therapy should be initiated according to the severity of organ involvement to inhibit progression to severe, irreversible disease. As new medications continue to be developed, the number of agents causing drug-induced vasculitis is expected to increase.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment change, Trial withdrawal: Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid (clinicaltrials.gov) - Jun 13, 2019
P=N/A, N=0, Withdrawn, Sponsor: University of California, Davis
As new medications continue to be developed, the number of agents causing drug-induced vasculitis is expected to increase. N=48 --> 0 | Recruiting --> Withdrawn
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Review, Journal: Development of a Practice Standard for Monitoring Adult Patients Receiving Bone-Modifying Agents at a Community Cancer Center. (Pubmed Central) - Jun 13, 2019
This recommendation will reduce laboratory draws and provide cost savings for patients. Compliance with dental clearance was fully achieved.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Añadir TPT a denosumab si tras 5 años seguimos en alto riesgo...🧐#osteoporosis #EULAR19 (Twitter) - Jun 13, 2019
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
You speak sense. And I do what you do for steroid-induced osteoporosis prevention. However the convenience of Denosumab is winning at least in Australia. Think Around 80% of market #EULAR2019 (Twitter) - Jun 12, 2019
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal, BRCA Biomarker: Clinical Impact of RANK Signalling in Ovarian Cancer. (Pubmed Central) - Jun 12, 2019
Our study independently links RANKL expression with poor clinical outcome in two unrelated OC cohorts. These findings implicate RANK signalling in the immunopathogenesis of OC and warrant clinical trials with denosumab in OC.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Zytiga (abiraterone acetate) / J&J
Journal: Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis. (Pubmed Central) - Jun 12, 2019
We like to call attention to the importance of prompt bone marrow examination once recognizing leukoerythroblastosis in patients with advanced prostate cancer. Survey of a possible coexistent disseminated intravascular coagulation is as well strongly recommended in this condition.